Colgate-Palmolive shares rise after upbeat fundamentals stay in focus and recent leadership moves

Colgate-Palmolive (CL) is up 4.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to investors leaning into Colgate-Palmolive’s steady consumer-staples profile following a strong start to 2026 and continued confidence in its outlook. Recent executive leadership appointments in its core oral care business, plus a recent bullish analyst reset (upgrade and higher price target), may also be contributing to incremental buying interest.

Details:

Colgate-Palmolive’s first-quarter 2026 update showed net sales up 8.4% year over year and organic sales growth of 2.9%.

On a non-GAAP “base business” basis, diluted EPS was reported at $0.97 versus $0.91 a year earlier, signaling underlying earnings momentum despite a lower GAAP EPS print.

The company maintained its full-year 2026 sales and EPS guidance while updating its full-year gross profit margin guidance.

Colgate-Palmolive announced Samir Singh as President, Enterprise Oral Care effective June 1, 2026, placing a new leader over the company’s flagship oral care portfolio.

Sources:

Colgate-Palmolive Investor Relations (SEC filing/earnings release), Zonebourse, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CL Insider Trading Activity

$CL insiders have traded $CL stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.

Here’s a breakdown of recent trading of $CL stock by insiders over the last 6 months:

STANLEY J III SUTULA (Chief Financial Officer) sold 97,843 shares for an estimated $9,223,287
PANAGIOTIS TSOURAPAS (COO, Eur., APac, Afr Eur, Skin) has made 0 purchases and 2 sales selling 50,000 shares for an estimated $4,778,436.
NOEL R. WALLACE (Chairman, President & CEO) sold 45,568 shares for an estimated $4,279,495
JENNIFER DANIELS (CLO and Secretary) sold 22,000 shares for an estimated $2,075,398
JOHN HAZLIN (Chief Growth Officer) sold 20,989 shares for an estimated $1,978,211
SALLY MASSEY (Chief Human Resources Officer) sold 15,851 shares for an estimated $1,506,287
GREGORY MALCOLM (EVP and Controller) has made 0 purchases and 2 sales selling 15,047 shares for an estimated $1,413,233.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive CL Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$CL Hedge Fund Activity

We have seen 896 institutional investors add shares of $CL stock to their portfolio, and 892 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BANK OF NEW YORK MELLON CORP added 7,927,238 shares (+172.5%) to their portfolio in Q1 2026, for an estimated $663,708,001
ACADIAN ASSET MANAGEMENT LLC added 4,779,753 shares (+151.4%) to their portfolio in Q1 2026, for an estimated $400,184,819
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO removed 4,606,766 shares (-98.9%) from their portfolio in Q1 2026, for an estimated $385,701,483
CITADEL ADVISORS LLC removed 4,040,509 shares (-55.9%) from their portfolio in Q1 2026, for an estimated $338,291,616
GOLDMAN SACHS GROUP INC added 3,983,616 shares (+72.5%) to their portfolio in Q1 2026, for an estimated $333,528,249
GQG PARTNERS LLC removed 3,969,183 shares (-34.9%) from their portfolio in Q4 2025, for an estimated $313,644,840
NORDEA INVESTMENT MANAGEMENT AB removed 3,495,538 shares (-74.9%) from their portfolio in Q1 2026, for an estimated $292,663,919

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$CL Analyst Ratings

Wall Street analysts have issued reports on $CL in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

JP Morgan issued a "Overweight" rating on 12/18/2025
RBC Capital issued a "Outperform" rating on 12/09/2025

To track analyst ratings and price targets for $CL, check out Quiver Quantitative's $CL forecast page.

$CL Price Targets

Multiple analysts have issued price targets for $CL recently. We have seen 14 analysts offer price targets for $CL in the last 6 months, with a median target of $97.0.

Here are some recent targets:

Lauren Lieberman from Barclays set a target price of $80.0 on 05/05/2026
Peter Grom from UBS set a target price of $100.0 on 05/04/2026
Andrea Teixeira from JP Morgan set a target price of $96.0 on 05/04/2026
Nik Modi from RBC Capital set a target price of $102.0 on 05/04/2026
Dara Mohsenian from Morgan Stanley set a target price of $95.0 on 04/23/2026
Edward Lewis from Rothschild & Co set a target price of $100.0 on 04/21/2026
Bryan Spillane from B of A Securities set a target price of $102.0 on 04/10/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.